Online inquiry

IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5819MR)

This product GTTS-WQ5819MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E gene. The antibody can be applied in Psoriasis, Type 1 diabetes research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916
UniProt ID P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5819MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4399MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-224818
GTTS-WQ14967MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SHR-1314
GTTS-WQ4936MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ5172MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ613MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ1358MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-874
GTTS-WQ14470MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ11189MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI0562
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW